CoChat

Neuroprotection of rhGLP‐1 in diabetic rats with cerebral ischemia/reperfusion injury via regulation of oxidative stress, EAAT2, and apoptosis

Fang, Yi, Jiang, Daoli, Wang, Yitong, Wang, Qian, Lv, Dongmei, Liu, Jichao, Liu, Chang · 2018 · Drug Development Research
Cited by 21

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Preclinical Research & Development The purpose of the present study is to evaluate the neuroprotective effect of recombinant human glucagon‐like peptide‐1 (rhGLP‐1) as well as to explore corresponding mechanisms in diabetic rats with cerebral ischemia/reperfusion injury induced by middle cerebral artery occlusion (MCAO). Diabetes mellitus was induced by intraperitoneal injection of streptozotocin. The rats were pretreated with rhGLP‐1 (20 μg/kg intraperitoneally, thrice a day) for 14 days. Thereafter, the rats were subjected to MCAO 90 min/reperfusion 24 hr. At 2 and 24 hr of reperfusion, the rats were assessed for neurological deficits and subsequently executed for the evaluation of cerebral infarct volume, oxidative stress parameters, and the expression of excitatory amino acid transporter 2 (EAAT2) and apoptotic markers. Results indicate that rhGLP‐1 significantly ameliorated neurological deficits and reduced cerebral infarct volume in diabetic MCAO rats. In addition, oxidative stress parameters in ischemic penumbra were significantly alleviated in rhGLP‐1‐pretreated diabetic MCAO rats. rhGLP‐1 significantly upregulated the ratio of Bcl‐2/Bax and EAAT2 expression and downregulated cleaved caspase‐3 expression in ischemic penumbra of diabetic MCAO rats. Our results suggest that rhGLP‐1 could significantly ameliorate neurological deficits and reduce cerebral infarct volume in diabetic MCAO rats, which may be due to the inhibition of oxidative stress and apoptosis and the promotion of EAAT2 expression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ddr.21439

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 63

  1. 10.1053/j.gastro.2007.03.054 · DOI · Paper page
  2. 10.1124/jpet.103.063222 · DOI
  3. 10.1016/j.brainres.2011.10.026 · DOI
  4. 10.1016/j.neuroscience.2014.09.064 · DOI
  5. 10.1007/s00125-004-1379-6 · DOI · Paper page
  6. 10.1038/s41598-017-02838-2 · DOI · Paper page
  7. 10.1007/s11064-004-6869-x · DOI · Paper page
  8. 10.1016/S0753-3322(98)80012-7 · DOI
  9. 10.1038/jcbfm.2009.47 · DOI · Paper page
  10. 10.1016/j.neuroscience.2013.10.038 · DOI
  11. 10.3390/ijms12107199 · DOI · Paper page
  12. 10.1161/01.STR.0000252091.36912.65 · DOI · Paper page
  13. Dinkova‐Kostova A. T., 2008, Direct and indirect antioxidant properties of inducers of cytoprotective proteins, Molecular Nutrition & Food Research, 52, S128
  14. 10.1016/S0140-6736(08)60694-7 · DOI · Paper page
  15. 10.1210/endo.142.2.7983 · doi:10.1210/endo.142.2.7983 · Paper page
  16. 10.2337/diabetes.53.2007.S96 · DOI · Paper page
  17. 10.1023/B:NERE.0000014832.78725.1a · DOI
  18. 10.1016/S0165-3806(01)00303-0 · DOI
  19. 10.1016/j.neurobiolaging.2010.02.014 · DOI · Paper page
  20. 10.1371/journal.pone.0089450 · DOI · Paper page
  21. 10.1161/01.STR.0000106916.81680.C0 · DOI
  22. 10.1038/sj.bjp.0707594 · DOI · Paper page
  23. 10.1007/978-3-7091-0693-8_49 · DOI
  24. 10.1097/WNR.0000000000000490 · DOI · Paper page
  25. 10.1111/j.1476-5381.2009.00486.x · DOI · Paper page
  26. 10.1371/journal.pone.0022135 · DOI · Paper page
  27. 10.1089/152308604771978372 · DOI
  28. 10.1530/JOE-13-0221 · DOI · Paper page
  29. 10.1111/j.1460-9568.2004.03554.x · doi:10.1111/j.1460-9568.2004.03554.x
  30. 10.1210/en.2002-220897 · DOI · Paper page
  31. 10.1001/archneur.58.8.1209 · DOI · Paper page
  32. 10.1002/jnr.22596 · DOI · Paper page
  33. 10.3233/JAD-2010-1314 · DOI · Paper page
  34. 10.1152/physrev.1999.79.4.1431 · DOI · Paper page
  35. 10.1161/01.STR.20.1.84 · DOI · Paper page
  36. 10.1016/S1474-4422(12)70005-4 · DOI · Paper page
  37. 10.1016/j.neuint.2012.11.009 · DOI · Paper page
  38. 10.1002/ana.410420310 · DOI · Paper page
  39. 10.1007/s10735-007-9102-9 · DOI
  40. 10.1016/j.devcel.2011.06.017 · DOI · Paper page
  41. 10.1016/j.neuropharm.2013.08.005 · DOI · Paper page
  42. 10.1007/s12035-007-8013-9 · DOI · Paper page
  43. 10.1155/2012/493934 · DOI
  44. 10.1007/978-3-319-08894-5_9 · DOI
  45. 10.1016/j.expneurol.2006.09.028 · DOI · Paper page
  46. 10.1124/jpet.300.3.958 · DOI · Paper page
  47. 10.1002/jnr.10611 · DOI · Paper page
  48. 10.1111/j.1460-9568.2001.01367.x · doi:10.1111/j.1460-9568.2001.01367.x · Paper page
  49. 10.1016/0896-6273(94)90038-8 · DOI · Paper page
  50. Ryden L., 2007, Guidelines on diabetes, pre‐diabetes, and cardiovascular diseases: Executive summary. The Task Force on diabetes and cardiovascular diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD), European Heart Journal, 28, 88
  51. 10.1016/S0006-8993(03)03117-2 · DOI
  52. 10.1089/ars.2010.3292 · DOI
  53. 10.1038/348443a0 · DOI · Paper page
  54. 10.1111/j.1440-1681.2004.04017.x · DOI · Paper page
  55. 10.1007/BF00241964 · DOI
  56. 10.1016/S0165-6147(98)01230-9 · DOI · Paper page
  57. 10.1016/S0140-6736(12)60738-7 · DOI · Paper page
  58. 10.1046/j.1460-9568.1998.00108.x · DOI · Paper page
  59. 10.1016/S0165-0270(98)00067-3 · DOI
  60. 10.1016/j.ejps.2015.01.010 · DOI
  61. 10.3390/molecules17032725 · doi:10.3390/molecules17032725
  62. 10.1046/j.1471-4159.2003.01756.x · DOI · Paper page
  63. 10.1016/j.brainres.2015.01.014 · DOI

Cited by

See all 21

Metadata

Authors
Fang, Y., Jiang, D., Wang, Y., Wang, Q., Lv, D., Liu, J., & Liu, C.
Venue
Drug Development Research
Publisher
Wiley
Published
2018-09
Volume
79
Issue
6
Pages
249-259
ISSN
  • 0272-4391 (ISSN-L)
  • 1098-2299
OpenAlex
W2891027425
Cited by
21
References
9
FWCI
1.29
Type
journal article
Language
en
Open access
closed
Funders
  • Peking University
  • Research and Development

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.